2. 学历类
  3. Text 3 In 2010,a federal judge shook Ame

Text 3 In 2010,a federal judge shook Ame

admin2022-08-02  52
问题 Text 3 In 2010,a federal judge shook America's biotech industry to its core.Companies had won patents for isolated DNA for decades—by 2005 some 20%of human genes were patented.But in March 2012 a judge ruled that genes were unpatentable.Executives were violently agitated.The Biotechnology Industry Organization（BIO）,a trade group,assured members that this was just a“preliminary step”in a longer battle.On July 29th they were relieved,at least temporarily.A federal appeals court overturned the prior decision,ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer.The chief executive of Myriad,a company in Utah,said the ruling was a blessing to firms and patients alike.But as companies continue their attempts at personalized medicine,the courts will remain rather busy.The Myriad case itself is probably not over.Critics make three main arguments against gene patents:a gene is a product of nature,so it may not be patented;gene patents suppress innovation rather than reward it;and patents’monopolies restrict access to genetic tests such as Myriad's.A growing number seem to agree.Last year a federal taskforce urged reform for patents related to genetic tests.In October the Department of Justice filed a brief in the Myriad case,arguing that an isolated DNA molecule“is no less a product of nature…than are cotton fibres that have been separated from cotton seeds.”Despite the appeals court's decision,big questions remain unanswered.For example,it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it.The case may yet reach the Supreme Court.As the industry advances,however,other suits may have an even greater impact.Companies are unlikely to file many more patents for human DNA molecules—most are unlikely patented or in the public domain.Firms are now studying how genes interact,looking for correlations that might be used to determine the causes of disease or predict a drug's efficacy.Companies are eager to win patents for“connecting the dots，”explains Hans Sauer,a lawyers for the BIO.Their success may be determined by a suit related to this issue,brought by the Mayo Clinic,which the Supreme Court will hear in its next term.The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents.Each meeting was packed.Generally speaking,the author's attitude toward gene patenting is_____A.criticalB.supportiveC.scornfulD.objective
选项 A.critical
B.supportive
C.scornful
D.objective
答案 D
解析 态度题【命题思路】这是一道作者观点态度题，需要结合全文信息在掌握文章主旨要义的基础上判断作者的态度，从而得出答案。【直击答案】文章主要讲述了基因专利申请的现状以及所遭遇的问题。文章第一、二段描述了基因专利申请的现状；第三段提出了反对基因申请专利的三个理由；第四段进一步阐述了基因专利申请过程中遇到的实际问题；第五段谈到其他的诉讼案件可能会对基因专利申请产生更大的影响；最后作者进一步提到相关的诉讼将会召开以解决基因专利申请的问题。由此看出，作者不仅提到了希望获得基因专利权的生物科技产业为此所做出的努力，同时也提到了反对者反对的理由，还提到了基因获得专利过程中遇到的实际问题。故而，作者对基因专利的描述中，态度是客观的，符合我们提到的理性原则，即正确答案往往比较客观理性，故D项为正确选项。【干扰排除】A项“批判的”，第三段提到了反对基因专利的人之所以反对的理由，但是作者并没有对此表示支持或反对。B项“支持的”，文章中有谈及生物技术公司为申请专利所做的努力，但作者没有掺入表示对其支持的观点。C项“嘲讽的”，在原文中作者只是客观谈及关于专利申请的事实，并没有体现嘲讽之意
转载请注明原文地址:http://tihaiku.com/xueli/2699879.html
本试题收录于： 英语二研究生题库研究生入学分类

英语二研究生

研究生入学

相关试题推荐
随机试题
最新回复(0)